Investing in SELLAS Life Sciences Group (NASDAQ:SLS) a year ago would have delivered you a 321% gain

This article was originally published on this site

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shareholders might be concerned after seeing the share price drop 26% in the last quarter. But that doesn’t change the fact that the returns over the last year have been spectacular. Few could complain about the impressive 321% rise, throughout the period. So the recent fall isn’t enough to negate the good performance. The real question is whether the fundamental business performance can justify the strong increase over the long term.

Now it’s worth having a look at the company’s fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.

Check out our latest analysis for SELLAS Life Sciences Group

SELLAS Life Sciences Group wasn’t profitable in the last twelve months, it is unlikely we’ll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. That’s because it’s hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth

If you are thinking of buying or selling SELLAS Life Sciences Group stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

It’s nice to see that SELLAS Life Sciences Group shareholders have gained 321% (in total) over the last year. This recent result is much better than the 22% drop suffered by shareholders each year (on average) over the last three. The optimist would say this is evidence that the stock has bottomed, and better days lie ahead. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that SELLAS Life Sciences Group is showing 4 warning signs in our investment analysis , and 2 of those are a bit concerning…

If you would prefer to check out another company — one with potentially superior financials — then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.